How to buy Sotorasib in the country?

Sotorasib is a revolutionary anti-cancer drug specifically designed to treat KRAS G12C mutated non-small cell lung cancer (NSCLC), a common genetic mutation in lung cancer. Sotorracib belongs to a class of drugs known as KRAS G12C inhibitors, and its unique mechanism of action has attracted widespread attention in the field of lung cancer treatment.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

Its mechanism of action is mainly to combat KRAS G12C mutant, which drives the abnormal growth and spread of cancer cells. Sotoracib specifically binds to the KRAS G12C protein, interferes with its active site, and blocks abnormal signaling pathways, thereby effectively inhibiting the proliferation and spread of cancer cells.

The drug was developed from a deep understanding of KRAS mutations in the treatment of lung cancer. Because KRAS mutations have long been considered difficult to target, the emergence of sotoraxib marks a huge breakthrough in this field. It represents the development of precision medicine, which focuses treatment more closely on an individual's genetic characteristics, providing new treatment options for some patients.

Clinical trial results show that sotoraxib is effective forKRAS G12CPatients with mutant non-small cell lung cancer exhibit significant anti-tumor activity. After patients receive treatment, their tumors may shrink or be stabilized, bringing new hope to patients with this specific subtype of lung cancer.